Purpose: Men are diagnosed with bladder cancer at 3 times the rate of women. However, women present with advanced disease and have poorer survival, suggesting delays in bladder cancer diagnosis. Hematuria is the presenting symptom in most cases. We assessed gender differences in hematuria evaluation in older adults with bladder cancer. Materials and Methods: Using the SEER (Surveillance, Epidemiology and End Results) cancer registry linked with Medicare claims we identified Medicare beneficiaries 66 years old or older diagnosed with bladder cancer between 2000 and 2007 with a claim for hematuria in the year before diagnosis. We examined the impact of gender, and demographic and clinical factors on time from initial hematuria claim to urology visit and on time from initial hematuria claim to hematuria evaluation, including cystoscopy, upper urinary tract imaging and urine cytology. Results: Of 35,646 patients with a hematuria claim in the year preceding bladder cancer diagnosis 97% had a urology visit claim. Mean time to urology visit was 27 days (range 0 to 377). Time to urology visit was longer for women than for men (adjusted HR 0.9, 95% CI 0.87e0.92). Women were more likely to undergo delayed (after greater than 30 days) hematuria evaluation (adjusted OR 1.13, 95% CI 1.07e1.21). Conclusions: We observed longer time to a urology visit for women than for men presenting with hematuria. These findings may explain stage differences in bladder cancer diagnosis and inform efforts to decrease gender disparities in bladder cancer stage and outcomes.
IN 2012 bladder cancer affected more than 70,000 Americans and caused almost 15,000 deaths. 1 Although men are diagnosed with bladder cancer at almost 3 times the rate of women, women present with more advanced disease and a greater proportion die of the disease. 2 Differences in stage distribution suggest that delayed diagnosis may explain at least some poorer outcomes observed in women. 3e5 More than 80% of bladder cancers are diagnosed after the presenting symptom of hematuria. 6 Hematuria is caused by benign and malignant conditions that vary by gender. In men hematuria typically arises from a source in the urinary tract, including kidney stones, bladder cancer or kidney cancer. In women hematuria may be attributable to urinary tract infection or gynecologic origins.
The AUA (American Urological Association) recommends diagnostic evaluation of hematuria that includes cystoscopy, urine cytology and upper urinary tract imaging. 7, 8 Any physician may order urine cytology and imaging but cystoscopy is performed almost exclusively by urologists. Despite clear guidelines for hematuria evaluation women may be referred to urologists less often and after a longer time since the first hematuria presentation than men. 9 However, prior studies of this question have been limited in scope, sample size and generalizability. 9e11 We estimated differences between men and women in the timeliness of hematuria evaluation and consultation with a urologist in a population based cohort of older patients with bladder cancer. We also identified predictors of delayed evaluation.
METHODS

Data
We used SEER cancer registry data linked with Medicare claims. SEER is a consortium of population based cancer registries in select states and areas that covers 30% of the population of the United States. 12 SEER collects information on the site and extent of disease, first course of cancer therapy, and date and cause of death. For adults 65 years old or older diagnosed with cancer in SEER areas cancer registry information is linked with Medicare claims for inpatient, outpatient and physician services. SEER-Medicare files were used in accordance with a data use agreement with the NCI (National Cancer Institute). This study was reviewed by the Memorial Sloan Kettering Cancer Center institutional review board and deemed exempt research.
Cohort
We identified patients 66 years old or older in whom primary bladder cancer was diagnosed between January 1, 2000 and December 31, 2007, and who had a claim for hematuria in the 12 months before bladder cancer diagnosis. We included in study patients with known cancer stage and continuous enrollment in Medicare Parts A and B for at least 1 year before bladder cancer diagnosis. We excluded those with prior malignancy and those enrolled in a Medicare managed care plan.
Outcomes
The primary outcome was time to first urology visit, defined as the interval between the first Medicare claim for hematuria in the year before bladder cancer diagnosis and the first claim for a urology visit. Urologists were identified by Medicare provider specialty code.
The secondary outcome was time to initiation of hematuria evaluation, defined as the interval between the first Medicare claim for hematuria in the year before bladder cancer diagnosis and the first claim for cystoscopy, upper urinary tract imaging or urine cytology. Upper tract imaging included computerized tomography urogram, renal ultrasound, retrograde pyelogram or excretory urogram. Delayed hematuria evaluation was defined as an interval of greater than 30 days between the first hematuria claim and the initiation of evaluation.
Covariates
The predictor of interest for each outcome was gender. On multivariable analysis we controlled for other characteristics, including age, race, marital status, median income in the census tract of residence, urban vs rural residence, comorbidity, geographic region, diagnosis year and specialty of the provider associated with the first claim for hematuria. Comorbidity was estimated using an adaptation of the Charlson comorbidity index based on claims in the year before bladder cancer diagnosis. 13 Provider specialty associated with the index hematuria claim of each patient was classified as primary care, obstetrics/ gynecology, urology or other. Primary care included internal medicine, family practice and general practice physicians, and nurse practitioners. Disease characteristics included bladder cancer stage, grade, histology and lymph node involvement. Stage was classified according to the AJCC (American Joint Committee on Cancer) staging scheme, 6th edition. 14 To control for a preexisting relationship with a urologist we created a binary indicator reflecting the presence or absence of any Medicare claim for an encounter with a urologist preceding the index hematuria claim in the year before bladder cancer diagnosis.
Analysis
Unadjusted associations between genders and the frequency of each outcome (urology visit, cystoscopy, upper tract imaging and cytology) were assessed by the chi-square test. We estimated Kaplan-Meier survival functions and the log rank tests to assess unadjusted associations between gender and time to a urology visit. We used Cox proportional hazards regression to estimate the impact of gender on time to the first urology visit after the index hematuria claim adjusting for demographic and disease characteristics. If the index hematuria claim coincided with a urology visit, time to the first urology visit was defined as a fraction of a day. Patients without a urology visit were censored at bladder cancer diagnosis.
We used logistic regression to estimate the impact of gender on the likelihood of delayed hematuria evaluation, adjusting for demographic and disease characteristics. There was a significant unadjusted association between the specialty of the provider associated with the index hematuria claim and a previous visit with a urologist. Thus, we included a single 4-level variable reflecting the interaction of these 2 terms, that is specialty of the provider associated with the index hematuria claim (urologist vs other) and claim for a urology visit in the year before the index hematuria claim (any vs none). All analysis was done with SASÒ, version 9.2.
RESULTS
We identified 41,229 patients with bladder cancer, of whom 35,646 (86%) had at least 1 claim with a hematuria diagnosis in the year before bladder cancer diagnosis. Of the 5,370 patients excluded from study 76% were male and 72% had a urology visit most commonly associated with codes for benign prostatic hyperplasia, urinary retention/ incontinence/other and bladder cancer. A total of 26,119 men (73%) and 9,527 women (27%) met our inclusion criteria. Compared with male patients females were older, more likely to be black and less likely to be married, resided in more affluent areas and had less comorbidity (supplementary table 1, http://jurology.com/). Women were more likely to have advanced stage bladder cancer and lymph node involvement. Men were more likely to have a urologist associated with the index hematuria claim (32% vs 24%) and more than twice as likely to have seen a urologist before the hematuria diagnosis (29% vs 13%).
Time to Urology Visit
Median time to the first urology visit was 3 days but this varied by gender, including 2 days for men and 6 for women. Mean time to the first urology visit was 27 days (range 0 to 377 days) but this also varied by gender, including 24 days for men and 35 for women. In an unadjusted comparison women had a slower time to the urology visit (log rank p <0.0001, see figure) . Controlling for demographic and disease characteristics, women were slower to see a urologist after the initial hematuria claim (adjusted HR 0.90, 95% CI 0.87e0.92, supplementary table 2, http://jurology.com/). Residence in a nonmetropolitan area, residence in the Midwest or West, greater comorbidity and high grade cancer were also associated with longer time to a urology visit. Patients who had seen a urologist previously were quicker to see a urologist after the hematuria diagnosis (adjusted HR 1.60, 95% CI 1.56e1.64).
Time to Hematuria Evaluation
Median time to the initiation of hematuria evaluation in the entire cohort was 8 days (range 0 to 378). Median times were similar for men and women (8 and 9 days, respectively). A claim for at least 1 component of hematuria evaluation was present in 87% of the cohort (table 1). Men were slightly more likely than women to undergo cystoscopy at some point before cancer diagnosis (72% vs 70%, p <0.001). The first procedure marking the initiation of hematuria evaluation was cystoscopy in 41% of the cohort, which was similar in men and women.
Of the 30,923 patients with any component of hematuria evaluation 7,941 (26%) experienced a delay of more than 1 month in initiation. Controlling for sociodemographic and disease characteristics, women were more likely to experience a delay than men (adjusted OR 1.12, 95% CI 1.05e1.20, table 2). Delayed evaluation was less likely among patients whose index hematuria claim was associated with a urologist (adjusted OR 0.26, 95% CI 0.24e0.29), who had seen a urologist in the year before hematuria diagnosis (adjusted OR 0.88, 95% CI 0.81e0.96) and in those with the 2 variables combined (adjusted OR 0.77, 95% CI 0.71e0.84).
Time to urology visit by gender
There was a trend toward greater odds of delay with more advanced tumor stage.
DISCUSSION
In this large cohort of older patients with bladder cancer we found substantial gaps in the timeliness of hematuria evaluations. Initiation of hematuria evaluation was delayed by a month or longer in a quarter of all patients and 13% received no component of a standard hematuria evaluation. We also found that women were slower to see a urologist after the initial presentation with hematuria.
Timely urology consultation following a hematuria diagnosis is important for several reasons. Cystoscopy is the only definitive test for visualizing bladder cancer and it is performed exclusively by urologists. In addition, most patients with bladder cancer are initially treated with transurethral resection of tumor, a surgical procedure performed almost exclusively by urologists. 15 Timely urology referral, especially for older adults, may be considered a benchmark for the quality of hematuria evaluation and bladder cancer management. Because urologists generally initiate bladder cancer treatment, a difference in the first urology visit could contribute to poorer oncologic outcomes in women with bladder cancer. 15 Several studies similarly documented poorer survival when the interval between a confirmed bladder cancer diagnosis and definitive treatment exceeded 3 months. 16, 17 Thus, we examined delayed evaluation as a secondary outcome, assuming that 1 month or longer between the first presentation with hematuria to a physician and the initiation of hematuria evaluation could result in overall treatment delays.
Our findings in a population based cohort are consistent with those of prior studies of institution and health plan based cohorts and physician surveys. In a study of 1,500 patients with risk factors for bladder cancer and documented microscopic hematuria 42% did not undergo a hematuria evaluation consistent with guidelines. 18 Among members of a large Midwestern health plan presenting with hematuria only 27% of women were referred to a urologist and women were referred more slowly than men. 9 A survey of almost 800 primary care physicians showed that only 46% of physicians in Miami and 26% in Dallas referred patients with microscopic hematuria to a urologist and not all patients with gross hematuria received a referral. 10 These studies and ours raise concern about systemic barriers to high quality and timely hematuria evaluation, particularly for women.
Several factors might explain the observed disparities in hematuria evaluation. Women may be erroneously treated for other diagnoses, such as urinary tract infections or postmenopausal bleeding, before being referred for further evaluation. In the large Midwestern health plan study women were more likely to be referred when they had recurring symptoms while men were more likely to be referred after a single episode of hematuria. 9 Women may take a more circuitous route through the health care system before seeing a urologist. Men may have an established relationship with a urologist while women may see a primary care physician or obstetrician/gynecologist before seeing a urologist. In our cohort men were more than twice as likely as women to have seen a urologist for any reason before a hematuria diagnosis and a previous encounter with a urologist was associated with more timely hematuria evaluation and an earlier urology visit. In a recent survey of 200 patients newly diagnosed with bladder cancer 78% of men vs 55% of women reported that they initially consulted a urologist due to urinary symptoms. 11 More women than men (16% vs 4%) were treated for 3 or more urinary tract infections in the year before the bladder cancer diagnosis. While this may be a consequence of men having an established relationship with a urologist, it may also reflect bias toward less aggressive testing and treatment of women, as in studies of cardiac care. 19 Even before seeing a health care provider women may wait to seek medical attention, perhaps because they attribute symptoms to benign etiologies or are complacent due to a lifetime of menstruation or prior urinary tract infections. 20 Investigation of the mechanisms of this disparity might inform targeted interventions to facilitate timely bladder cancer evaluation and treatment in women.
Our study raises concern about how hematuria evaluations are done and whether the care recommended under current guidelines is appropriate. Although few patients who present with hematuria have bladder cancer, hematuria is the initial presenting symptom in more than 80% of patients with bladder cancer. 6, 21 Therefore, in the absence of effective screening for bladder cancer the AUA currently recommends a thorough evaluation of persistent, asymptomatic microscopic hematuria when benign urological conditions have been ruled out. 7 The costs and risks of invasive tests such as cystoscopy may be substantial. 22 Thus, some experts proposed a risk stratified approach to hematuria evaluation rather than subjecting all patients to all recommended diagnostic tests. 21 Several limitations of our study should be noted. 1) Our results may not be applicable to privately insured patients or those younger than 66 years.
2) We had no information on smoking history, an important risk factor for bladder cancer. Smokers may have established relationships with health care professionals, receive closer monitoring for smoking related illnesses or be referred for symptom evaluation more quickly. 3) We defined hematuria onset by the presence of a Medicare claim with the relevant diagnosis code. If patients waited or experienced recurrent hematuria episodes before seeking care, our analysis underestimates the magnitude of delay.
Despite these limitations our findings suggest that there are opportunities for improvement in the timeliness of hematuria evaluation in patients who are ultimately diagnosed with bladder cancer. Our results also suggest that women are susceptible to delays in referral to a urologist and are at greater risk for delayed hematuria evaluation. These findings raise questions about systemic forces underlying gender disparities, particularly for urology visits. Further investigation may better elucidate the mechanisms of observed gender differences in hematuria evaluation. In conclusion, at the least educational interventions regarding urological health for women and quality improvement programs for providers and health systems could begin to close the gender gap in hematuria evaluation, hopefully decreasing disparities in bladder cancer survival. 
